Regeneron Pharmaceuticals
REGN
1,164 hedge funds and large institutions have $66.2B invested in Regeneron Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 88 funds opening new positions, 400 increasing their positions, 465 reducing their positions, and 107 closing their positions.
2% less funds holding
Funds holding: 1,191 → 1,164 (-27)
6.37% less ownership
Funds ownership: 92.19% → 85.82% (-6.4%)
13% less capital invested
Capital invested by funds: $76.1B → $66.2B (-$9.94B)
14% less call options, than puts
Call options by funds: $1.45B | Put options by funds: $1.68B
14% less repeat investments, than reductions
Existing positions increased: 400 | Existing positions reduced: 465
18% less first-time investments, than exits
New positions opened: 88 | Existing positions closed: 107
33% less funds holding in top 10
Funds holding in top 10: 42 → 28 (-14)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$619M |
| 2 |
JP Morgan Chase
New York
|
+$154M |
| 3 |
D.E. Shaw & Co
New York
|
+$105M |
| 4 |
Man Group
London,
United Kingdom
|
+$89.9M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$86.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EWA
EP Wealth Advisors
Torrance,
California
|
-$3.07B |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
-$1.43B |
| 3 |
BlackRock
New York
|
-$256M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$216M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$207M |
REGN Hedge Fund Activity: Q2 2023 in Review
1,164 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q2 2023, worth a combined $66.2B — down 13% from $76.1B a quarter earlier.
Sellers outnumbered buyers: 107 funds closed out of REGN and 88 opened new positions — a net loss of 19 holders — while 465 trimmed existing stakes and 400 added.
The largest buyer was Capital International Investors, adding an estimated $619M. The largest seller was EP Wealth Advisors, cutting an estimated $3.07B.
- 1,164 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q2 2023, down from 1,191 in Q1 2023.
- Funds reported $66.2B of Regeneron Pharmaceuticals stock for Q2 2023, down 13% quarter-over-quarter.
- 88 funds opened new Regeneron Pharmaceuticals positions in Q2 2023 and 107 closed out, a net change of -19 holders.
- The largest Regeneron Pharmaceuticals buyer in Q2 2023 was Capital International Investors, an estimated $619M added.
- The largest Regeneron Pharmaceuticals seller in Q2 2023 was EP Wealth Advisors, an estimated $3.07B sold.
Based on aggregated 13F filings for Q2 2023.